Etrasimod:一种用于治疗溃疡性结肠炎的磷脂酰肌苷-1-磷酸受体调节剂。

IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Annals of Pharmacotherapy Pub Date : 2024-10-01 Epub Date: 2024-01-23 DOI:10.1177/10600280231225770
David Choi, Michelle Becker, Marina Ivanov, Shubha Bhat
{"title":"Etrasimod:一种用于治疗溃疡性结肠炎的磷脂酰肌苷-1-磷酸受体调节剂。","authors":"David Choi, Michelle Becker, Marina Ivanov, Shubha Bhat","doi":"10.1177/10600280231225770","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To review the pharmacologic and clinical profile of etrasimod in the treatment of ulcerative colitis (UC).</p><p><strong>Data sources: </strong>A PubMed search was conducted from inception to November 2023 using the keywords <i>etrasimod</i>, <i>ulcerative colitis</i>, <i>and sphingosine-1-phosphate receptor modulator</i>. Information was also obtained from published abstracts and package insert.</p><p><strong>Study selection and data extraction: </strong>Phase 2 and 3 studies plus relevant literature on etrasimod pharmacologic and clinical profile were reviewed.</p><p><strong>Data synthesis: </strong>Per ELEVATE, 2 phase 3 studies, a higher proportion of patients with moderately to severely active UC achieved clinical remission in the induction and maintenance phase with etrasimod compared with placebo. In addition, a higher proportion of patients achieved secondary endpoints of clinical response, endoscopic improvement-histologic remission, corticosteroid-free remission, and endoscopic improvement with etrasimod vs placebo. Common adverse events include anemia and headache.</p><p><strong>Relevance to patient care and clinical practice in comparison with existing drugs: </strong>Etrasimod is now the second orally administered sphingosine-1-phosphate modulator approved for UC, providing patients with additional treatment options. Efficacy rates of this treatment are in line with other UC medication options. Similar to other sphingosine-1-phosphate receptor modulators, various assessments are required at baseline and during treatment to ensure safe and appropriate use.</p><p><strong>Conclusion: </strong>Etrasimod is another possibility in the armamentarium of UC treatment, providing patients with more oral medication options. Prior to treatment initiation, several assessments relating to safety, drug interactions, and pharmacogenomics factors are advised.</p>","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"1054-1063"},"PeriodicalIF":2.3000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Etrasimod: A Sphingosine-1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis.\",\"authors\":\"David Choi, Michelle Becker, Marina Ivanov, Shubha Bhat\",\"doi\":\"10.1177/10600280231225770\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To review the pharmacologic and clinical profile of etrasimod in the treatment of ulcerative colitis (UC).</p><p><strong>Data sources: </strong>A PubMed search was conducted from inception to November 2023 using the keywords <i>etrasimod</i>, <i>ulcerative colitis</i>, <i>and sphingosine-1-phosphate receptor modulator</i>. Information was also obtained from published abstracts and package insert.</p><p><strong>Study selection and data extraction: </strong>Phase 2 and 3 studies plus relevant literature on etrasimod pharmacologic and clinical profile were reviewed.</p><p><strong>Data synthesis: </strong>Per ELEVATE, 2 phase 3 studies, a higher proportion of patients with moderately to severely active UC achieved clinical remission in the induction and maintenance phase with etrasimod compared with placebo. In addition, a higher proportion of patients achieved secondary endpoints of clinical response, endoscopic improvement-histologic remission, corticosteroid-free remission, and endoscopic improvement with etrasimod vs placebo. Common adverse events include anemia and headache.</p><p><strong>Relevance to patient care and clinical practice in comparison with existing drugs: </strong>Etrasimod is now the second orally administered sphingosine-1-phosphate modulator approved for UC, providing patients with additional treatment options. Efficacy rates of this treatment are in line with other UC medication options. Similar to other sphingosine-1-phosphate receptor modulators, various assessments are required at baseline and during treatment to ensure safe and appropriate use.</p><p><strong>Conclusion: </strong>Etrasimod is another possibility in the armamentarium of UC treatment, providing patients with more oral medication options. Prior to treatment initiation, several assessments relating to safety, drug interactions, and pharmacogenomics factors are advised.</p>\",\"PeriodicalId\":7933,\"journal\":{\"name\":\"Annals of Pharmacotherapy\",\"volume\":\" \",\"pages\":\"1054-1063\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Pharmacotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/10600280231225770\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10600280231225770","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

目的:回顾依曲莫德治疗溃疡性结肠炎(UC)的药理和临床概况:回顾依曲莫德治疗溃疡性结肠炎(UC)的药理和临床概况:以etrasimod、溃疡性结肠炎和鞘氨醇-1-磷酸受体调节剂为关键词,在PubMed上进行了从开始到2023年11月的检索。研究选择和数据提取:回顾了2期和3期研究以及有关依曲莫德药理和临床概况的相关文献:根据ELEVATE和2项3期研究,与安慰剂相比,中重度活动性UC患者在依曲莫德诱导和维持阶段获得临床缓解的比例更高。此外,与安慰剂相比,使用依曲莫德达到临床应答、内镜改善-组织学缓解、无皮质类固醇缓解和内镜改善等次要终点的患者比例更高。常见不良反应包括贫血和头痛:Etrasimod是目前第二种获准用于UC的口服鞘磷脂-1-磷酸调节剂,为患者提供了更多的治疗选择。该疗法的有效率与其他治疗 UC 的药物一致。与其他鞘氨醇-1-磷酸受体调节剂类似,在基线和治疗过程中也需要进行各种评估,以确保安全和合理使用:结论:Etrasimod是治疗多发性硬化症药物库中的另一种可能性,为患者提供了更多的口服药物选择。在开始治疗前,建议对安全性、药物相互作用和药物基因组学因素进行多项评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Etrasimod: A Sphingosine-1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis.

Objective: To review the pharmacologic and clinical profile of etrasimod in the treatment of ulcerative colitis (UC).

Data sources: A PubMed search was conducted from inception to November 2023 using the keywords etrasimod, ulcerative colitis, and sphingosine-1-phosphate receptor modulator. Information was also obtained from published abstracts and package insert.

Study selection and data extraction: Phase 2 and 3 studies plus relevant literature on etrasimod pharmacologic and clinical profile were reviewed.

Data synthesis: Per ELEVATE, 2 phase 3 studies, a higher proportion of patients with moderately to severely active UC achieved clinical remission in the induction and maintenance phase with etrasimod compared with placebo. In addition, a higher proportion of patients achieved secondary endpoints of clinical response, endoscopic improvement-histologic remission, corticosteroid-free remission, and endoscopic improvement with etrasimod vs placebo. Common adverse events include anemia and headache.

Relevance to patient care and clinical practice in comparison with existing drugs: Etrasimod is now the second orally administered sphingosine-1-phosphate modulator approved for UC, providing patients with additional treatment options. Efficacy rates of this treatment are in line with other UC medication options. Similar to other sphingosine-1-phosphate receptor modulators, various assessments are required at baseline and during treatment to ensure safe and appropriate use.

Conclusion: Etrasimod is another possibility in the armamentarium of UC treatment, providing patients with more oral medication options. Prior to treatment initiation, several assessments relating to safety, drug interactions, and pharmacogenomics factors are advised.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.70
自引率
0.00%
发文量
166
审稿时长
3-8 weeks
期刊介绍: Annals of Pharmacotherapy (AOP) is a peer-reviewed journal that advances pharmacotherapy throughout the world by publishing high-quality research and review articles to achieve the most desired health outcomes.The articles provide cutting-edge information about the most efficient, safe and cost-effective pharmacotherapy for the treatment and prevention of various illnesses. This journal is a member of the Committee on Publication Ethics (COPE). Average time from submission to first decision: 14 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信